Carel J C, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, Chaussain J L
INSERM U342, University Paris V, Hôpital Saint Vincent de Paul, France.
Eur J Endocrinol. 1995 Jun;132(6):699-704. doi: 10.1530/eje.0.1320699.
We evaluated the pituitary and gonadal suppression in 40 girls and nine boys treated with depot leuprorelin (3.75 mg sc if body weight > or = 20 kg, 1.87 mg if body weight < 20 kg) every 28 days for central precocious puberty. Gonadal suppression was obtained in most of the children with this dose: 3 months after initiation of the treatment, 85% of children had a peak plasma luteinizing hormone response to gonadotropin-releasing hormone < 3 IU/l and the gonadal axis remained suppressed throughout the duration of the study (up to 24 months). Four patients required higher doses of leuprorelin to achieve suppression. In two girls, a cutaneous reaction to the drug was associated with incomplete suppression and the treatment had to be interrupted. Plasma leuprorelin levels tended to increase from day 3 to day 28 after injection. Residual leuprorelin levels measured 28 days after injection were stable during the first year of the study. We conclude that an initial dose of depot leuprorelin of 3.75 mg sc every 28 days is efficient in most children with central precocious puberty.
我们评估了40名女孩和9名男孩使用长效亮丙瑞林（体重≥20 kg者皮下注射3.75 mg，体重＜20 kg者皮下注射1.87 mg）每28天治疗中枢性性早熟时垂体和性腺的抑制情况。大多数儿童使用该剂量可实现性腺抑制：治疗开始3个月后，85%的儿童促性腺激素释放激素刺激试验中促黄体生成素峰值＜3 IU/l，并且在整个研究期间（长达24个月）性腺轴持续受到抑制。4例患者需要更高剂量的亮丙瑞林才能实现抑制。在2名女孩中，药物的皮肤反应与抑制不完全相关，治疗不得不中断。注射后血浆亮丙瑞林水平从第3天到第28天呈上升趋势。注射后28天测得的残余亮丙瑞林水平在研究的第一年保持稳定。我们得出结论，对于大多数中枢性性早熟儿童，每28天皮下注射3.75 mg长效亮丙瑞林的初始剂量是有效的。
